

# **Peptidylarginine Deiminase inhibition abolishes the production of large extracellular vesicles from *Giardia intestinalis*, affecting host-pathogen interactions by hindering adhesion to host cells.**

Bruno Gavinho <sup>1</sup>, Izadora Volpato Rossi <sup>2</sup>, Ingrid Evans-Osses <sup>3</sup>, Sigrun Lange <sup>4</sup>  
and Marcel Ivan Ramirez <sup>5,6</sup> \*

- 1- Programa de pós-graduação em Microbiologia, Parasitologia e Patologia, Universidade Federal do Paraná. PR, Brasil.
- 2- Programa de pós-graduação em Biologia Celular e Molecular, Universidade Federal do Paraná. PR, Brasil.
- 3- Departamento de Enfermagem, Faculdades Santa Cruz, Curitiba, PR, Brasil.
- 4- Tissue Architecture and Regeneration Research Group, School of Life Sciences, University of Westminster, London, United Kingdom.
- 5- Departamento de Bioquímica e Biologia Molecular, Universidade Federal do Paraná, PR, Brasil.
- 6- Instituto Oswaldo Cruz, Rio de Janeiro, Brasil

Correspondence author: [marcel.ivan.ramirez@gmail.com](mailto:marcel.ivan.ramirez@gmail.com)

Running title: Large extracellular vesicle inhibition in *Giardia intestinalis* by PAD-inhibitor and CBD.

## Abstract

*Giardia intestinalis* is an anaerobic protozoan that is an important etiologic agent of inflammation-driven diarrhea worldwide. Although self-limiting, a deep understanding of the factors involved in the pathogenicity that produces the disruption of the intestinal barrier remains unknown. There is evidence that under diverse conditions, the parasite is capable of shedding extracellular vesicles (EVs) which could modulate the physiopathology of giardiasis. Here we describe new insights of *G. intestinalis* EV production, revealing its capacity to shed two different enriched EV populations (large and small extracellular vesicles) and identified a relevant adhesion function associated only with the larger population. Our work also aimed at assessing the influences of two recently identified inhibitors of EV release in mammalian cells, namely peptidylarginine deiminase (PAD) inhibitor and cannabidiol (CBD), on EV release from *Giardia* and their putative effects on host-pathogen interactions. PAD-inhibitor Cl-amidine and CBD were both able to effectively reduce EV shedding, the PAD-inhibitor specifically affecting the release of large extracellular vesicles and interfering with *in vitro* host-pathogen interactions. The strong efficacy of the PAD-inhibitor on *Giardia* EV release indicates a phylogenetically conserved pathway of PAD-mediated EV release, most likely affecting the *Giardia* arginine deiminase (GiADI) homolog of mammalian PADs. While there is still much to learn about *G. intestinalis* interaction with its host, our results suggest that large and small EVs may be differently involved in protozoa communication, and that EV-inhibitor treatment may be a novel strategy for recurrent giardiasis treatment.

Keywords: Host-Pathogen interaction; Extracellular vesicles; *Giardia intestinalis*; Peptidylarginine deiminase inhibitor, Cannabidiol (CBD)

## Introduction

*Giardia intestinalis* is a lumen dwelling pathogen in the vertebrate gut, responsible for a worldwide waterborne diarrhea known as giardiasis. The flagellated protozoa was formerly incorporated in the WHO neglected diseases, estimated a burden not only for poor, but also industrialized countries (Savioli et al., 2006). Approximately 300 million infections are identified annually, mainly in children (reviewed by Ankarklev et al., 2010; Cernikova et al., 2018). Its life cycle consists of two evolutionary stages: i) the trophozoite, which adheres to the intestinal mucosal barrier and multiplies by binary fission, and ii) the infectious stage, the cyst, that is released through feces and is acquired by ingestion of food or water,. Although not invasive, this extracellular protozoa has a distinct cellular structure due to evolutionary reduction (Cernikova et al., 2018). *G. intestinalis* interaction with the host, and its immune evasion, are mediated through many survival factors, including inhibition of neutrophil migration through cathepsin B (Cotton et al., 2015), arginine and cytokine suppression by arginine deiminases (Touz et al., 2018), induction of epithelial translocation through cysteine proteases (Liu et al., 2018), anti-oxidant production, microvillus shortening (reviewed by Bartelt & Sartor, 2015), dysbiosis (Barash et al., 2017; Bartelt et al., 2017) and antigenic variation (Prucca et al., 2008; Serradel et al., 2016). A complete comprehension of the pathogenesis is still elusive, and many factors are involved in the persistence of trophozoites on the host, including drug resistance (Serradell et al., 2016). Finally, chronic infection is a significant concern in giardiasis, due to sequelae related to nutritional and cognitive deficiency in children and immunocompromised individuals (Halliez & Buret, 2013; Bartelt & Sartor, 2015). Adaptions of the parasite for survival in the host involve sophisticated forms of host-pathogen communication. Many reports have described the release of extracellular vesicles (EVs) from pathogens to be relevant to disease status (Cwiklinski et al., 2015; Coakley et al., 2017). EVs are found in most biological fluids and are 30-1000 nm lipid-bilayer vesicles, which are shed from cells and transport a range of biomolecules, participating in cell communication in physiological and pathophysiological processes (Coakley et al., 2015; Maas et

al., 2017; van Niel et al., 2018; Ramirez et al., 2018; Ryu et al., 2018). Our group has previously described EV release of *G. intestinalis* and established that protozoa EVs are involved in pathogen interactions via immunomodulation and trophozoite persistence (Evans-Osses et al., 2017). In recent years, there has been a growing interest to improve current knowledge of the nature, constitution and biogenesis of all secreted EVs. Lately, the field of EVs is debating the need to accurately separate EV subtypes to investigate functional relevance (Tckach et al., 2018; Slomka et al., 2018). Enrichment of subpopulations of EVs from samples is acquired based on differential centrifugation steps: large EVs (LEVs) are obtained at speeds lower than 20,000xg and small EVs (SEVs) are pelleted at 100.000xg in a further ultracentrifugation step. Formerly, microvesicles and exosomes, particularly present in LEV and SEV respectively, are considered the main EV subpopulations. Exosomes are the smallest population, continually produced in the late endosome and liberated through the fusion of multivesicular bodies within the plasma membrane. Microvesicles are particles of a bigger size produced through a budding from the plasma membrane under stress mediated by scramblase, calpain and  $Ca^{2+}$  liberation (Morrison et al., 2016). Different roles for these EV subpopulations remain a focus of ongoing investigations; are all EVs phenotypically relevant and/or similar? Another aspect of great importance is EV cargo and its modulation during biological processes or via drug-treatment. There is growing evidence that nucleic acids are also found in protozoa EVs, including dsDNA, tRNA, rRNA and small RNAs that could modulate gene expression from recipient cells (Kim et al., 2017; Tsatsaronis et al., 2018). The identification of the involvement of nucleic acids generated by pathogen or host cells, and transferred through EVs, have initiated a new platform for investigation in parasitology (Coakley et al., 2015).

While it is known that EVs are released by multiple mechanisms, some advances in understanding of their biogenesis has been elucidated via studies on the peptidylarginine deiminase (PAD)-mediated pathway of EV release (Kholia et al., 2015; Kosgodage et al., 2017; Lange et al., 2017; Kosgodage et al., 2018a). PADs are phylogenetically conserved enzymes from bacteria to mammals (Vossenaar et al., 2003; Magnadottir et al., 2018), including in *Giardia* (arginine deiminase GiADI; Trejo-Soto et al., 2016). PADs catalyze post-

translational deimination by irreversibly changing arginine into citrulline in a calcium-catalyzed manner in target proteins, affecting their folding and function (Vossenaar et al., 2003; György et al., 2006). PADs are involved in physiological and pathophysiological processes and their upregulation and associated increase in deiminated proteins is associated with various pathologies including autoimmune and neurodegenerative diseases as well as cancer (Vossenaar et al., 2003; Wang and Wang 2013; Witalison et al., 2015; Lange et al., 2017). While exact roles for PADs in EV biogenesis and release remain to be fully elucidated, effects on cytoskeletal, nuclear and mitochondrial proteins have been reported (Kholia et al., 2015; Kosgodage et al., 2018). As pharmacological PAD-inhibitors have previously been shown to be potent inhibitors of EV release in various cancer cells, as well as to modulate EV cargo (Kholia et al., 2015; Kosgodage et al., 2017; Kosgodage et al., 2018a), we sought to investigate a phylogenetically conserved influence of such PAD-inhibitors on the EV production of our protozoa model; putatively targeting GiADI and therefore also reveal a role for GiADI in EV release.

In addition, cannabidiol (CBD), a phytocannabinoid derived from *Cannabis sativa* (Mechoulam et al., 2002) was recently identified as a potent EV-inhibitor in cancer cells (Kosgodage et al., 2018b, Kosgodage et al., 2019). As cannabinoids have previously been associated with anti-parasitic functions (Nok et al., 1994, Croxford et al., 2005; Roulette et al., 2016) and immunoregulatory roles during infectious disease (reviewed in Hernández-Cervantes et al., 2017) we sought to identify whether EV release from *Giardia* may be affected by CBD, thus elucidating a novel aspect of CBD function on *Giardia*-host interaction.

Here, we report that *G. intestinalis* produces two populations of EVs that differ in size. The larger EV population had a significant effect on protozoa-host adhesion *in vitro* and was significantly reduced by both PAD-inhibitor and CBD. In addition, treatment with PAD-inhibitor selectively prevented protozoa EV production.

## Methods

**G. intestinalis isolates and cell culture:** *G. intestinalis* isolate WB (ATCC 50803) were grown in TYI-S-33 medium (Keister, 1983) supplemented with 10% adult bovine serum with 1% Penicillin/Streptomycin 1000 U (Gibco™) and

0.05% bovine bile (ThermoFisher™) at 37°C under microaerophilic conditions. The cultures were maintained until confluent and thereafter sub-cultured, each for 72 hours. Human colorectal adenocarcinoma cells, caco-2 (ATCC CRL-2102) were cultured in RPMI supplemented with 10% fetal calf serum and 1% Penicillin/Streptomycin 1000 U (Gibco™). Cells were incubated at 37°C, 5% CO<sub>2</sub> until a confluent cell monolayer was reached.

**EV isolation:** Parasites from confluent cultures were decanted by chilling for 15 min in ice-cold, centrifuged twice (600xg/5min) and the pellets suspended with fresh TYI-S-33 without adult bovine serum (FBS). Parasites were then counted using a hemocytometer, and diluted to  $1 \times 10^6$  per sample according to Evans-Osses et al.(2017). 1mM of CaCl<sub>2</sub> were added to the parasite culture for EV induction and incubated for 1 hour at 37°C. Then, EV pellets were collected via step-wise centrifugation: first, at 600xg/5 min; 4000xg/30 min to eliminate cellular debris, thereafter the supernatant was centrifuged at 15,000xg for 1h and the resulting pellet was washed and resuspended in phosphate buffered saline (PBS). The remaining supernatant was then ultracentrifuged for 100,000xg for 4h, and the resulting EV-containing pellets were washed once in PBS. Both samples were kept at 4°C until further use. To determine cell viability post-EV isolation, parasites were adjusted to  $1 \times 10^6$  per sample and submitted to the vesiculation protocol for 1, 3 or 6 hours. Then, trophozoite pellets were subcultured. For mammalian EV purification, caco-2 were cultured until confluence, and then medium was removed. Cultures were washed twice with fresh RPMI-1640 and kept for 1 h with medium without FBS. The supernatant was processed in the same manner as for protozoa.

**EV Quantification and Characterization:** EVs were in the first instance quantified based on their protein concentrations by the Micro BCA assay (ThermoFisher™). For Nanoparticle tracking analysis (NTA, Nanosight, Malvern, U.K.), each sample was diluted 1:100 in PBS and subjected to a NS300 Nanosight, with readings performed in triplicate during 60 s videos at 10 frames per second at room temperature, with the following parameters: camera shutter – 1492, camera gain – 512, detection threshold – 10. The resulting replicate histograms were averaged for presentation in box-plots.

**Treatment of trophozoites with EV-inhibitors:** Inoculum of  $10^6$  trophozoites per group (triplicates) were stimulated with 1 mM  $\text{CaCl}_2$  for the production of EVs in microtubes with or without EV-inhibitors. Groups were as follows: medium only (control), 100 or 50  $\mu\text{M}$  PAD-inhibitor Cl-amidine (a kind gift from Prof Paul Thompson, UMASS), or with 10 or 5  $\mu\text{M}$  CBD (90899\_SIAL, Sigma-Aldrich™). After 60 minutes of incubation ( $37^\circ\text{C}$ ), samples were processed according to Evans-Osses et al (2017).

**Host-pathogen interaction assay after exposure with EV-inhibitors:** caco-2 were seeded in 24-well plates and grown to 100% confluence. Inoculations of  $5 \times 10^5$  trophozoites per group were submitted to the EV production and then transferred to the cell monolayer for 3 hours ( $37^\circ\text{C}$ ) in a final volume of 1 mL / well (MOI 10:1). The following groups were investigated: medium only (control), 10  $\mu\text{M}$  CBD, 10  $\mu\text{M}$  CBD + 14  $\mu\text{g}$  EVs, 100  $\mu\text{M}$  Cl-amidine, 100  $\mu\text{M}$  Cl-amidine + 14  $\mu\text{g}$  EVs. After incubation, the trophozoites quantification was performed after removal of the supernatant, centrifuging non-adherent parasites and counting them using a hemacytometer. The percentage of trophozoites adhering to caco-2 cells was subsequently calculated according to Cotton et al. (2015). In experiments assessing the effects of mammalian EVs on trophozoite adhesion, caco-2 cells were grown until confluence, then the medium was removed and wells were washed and maintained with medium without FBS. Monolayers were thereafter treated with 100  $\mu\text{M}$  Cl-amidine, for 1 h, followed by incubation with  $5 \times 10^5$  trophozoites per well. Experimental groups were as follows: 7 or 14  $\mu\text{g}$  caco-2 SEVs, 7 or 14  $\mu\text{g}$  caco-2 LEVs. Statistical analysis was performed by one-way ANOVA ( $p < 0.0001$ ).

**EV staining:** For uptake assays, EVs were stained and tested with carboxyfluorescein succinimidyl ester (CFSE, ThermoFisher™) or with the lipophilic dye PKH-26 (SigmaAldrich™). For CFSE labelling, 1  $\mu\text{L}$  of the fluorescent dye was diluted with both EV populations in 1 mL PBS. For PKH-26, 2  $\mu\text{L}$  of the fluorescent dye were diluted in 1 mL of diluent C and both EV populations were diluted 1/40 in diluent C. Both dilutions were mixed together at a volume ratio of 1:1. For both fluorescent dyes, labelling was continued for 15 min at room temperature in the dark. The reaction was stopped by adding 1 mL

FBS, and samples were then washed in PBS, and ultracentrifuged at at 15.000xg for 1 h to obtain LEVs and at 100,000xg for 4 h for collection of SEV.

**Protozoan EVs uptake by caco-2 cells:** Caco-2 cells were incubated on sterile coverslips at 37°C in 5% CO<sub>2</sub> with 3.5 or 14 µg of PKH26-labeled protozoal EVs (ThermoFisher™) for 1h. Caco-2 monolayers were also labelled for nuclei (DAPI, blue - ThermoFisher™). After incubation, the cells were extensively washed in cold PBS, and fixed with 4 % paraformaldehyde. Coverslips were washed with PBS and mounted with 10 µl of a 50 % glycerol solution. Internalized EVs were detected by confocal microscopy (Nikon A1R HD Multifoton Confocal). Images were processed by Image J software (v. 1.48 – open source, Schneider et al., 2012). Fluorescence intensity of two images per sample were obtained in a duplicate experiment, and corrected cellular fluorescence was estimated as in McCloy et al (2014).

**Cytotoxicity Assay of EV-inhibitors toward caco-2 cells:** Caco-2 were seeded into a 96-well plate and grown at 37°C in 5% CO<sub>2</sub> until confluence in RPMI-1640 medium containing 10% fetal bovine serum and 1% penicillin/streptomycin (10 000 UI). Cells were treated with albendazole (ABZ) at 10 µM, 100 µM Cl-amidine and 10 µM CBD, and the volume was adjusted to 100 µL of RPMI per well. After 48 hours, wells were washed with 100 µL of PBS (50%). Cells were fixed with methanol (50 µL) for 10 min, after which 50 µL of crystal violet 0.2% in ethanol/water (2% V/V) were added to each tube. After 2 min, the wells were exhaustively washed with 200 µL of PBS. Elution was made with a sodium citrate solution (0.05 µmol, 10 min), and absorbance was determined at 540 nm on a plate spectrophotometer.

## Results

### ***Giardia EV Biogenesis: identification of two distinct populations***

The first objective was to obtain different EV populations from *G. intestinalis*. The previous protocol (Evans-Osses et al., 2017) was slightly modified to



separate putative large extracellular (LEV) and small extracellular vesicles (SEV) from the total extracellular vesicles described before (Fig.1A). Two different EV populations were recovered from this method: LEVs at 15,000xg and SEVs at 100,000xg. The protocol was performed for protozoa and mammalian host cells. Protein estimation (Fig.1B) and nanoparticle tracking analysis (Fig.1C) showed a higher yield of protozoa EVs than caco-2 (~3 fold higher). In addition, *Giardia* is capable of shedding more LEVs (~ 3 fold higher than SEVs). LEV and SEV fractions showed a respective mean vesicle diameter of 187.6 and 67.7 nm respectively (Fig.1E-F). We also investigated cell viability after stimulating trophozoites to produce EVs for 1, 3 and 6 hours respectively, following the growth curve in a complete medium by 72 h at 37°C, 5%CO<sub>2</sub>. Parasites stimulated for 1 h-EV production maintained a normal growth (Fig. 1D). Parasites stimulated for EV production for 3 and 6 h only reached confluence after more than 72 h, therefore not maintaining normal growth rate.

### ***PAD-inhibitor and CBD treatment affects Giardia EV biogenesis***

*G. intestinalis* trophozoites were treated with PAD-inhibitor Cl-amidine or CBD respectively to investigate their ability to inhibit EV production. Both compounds were able to significantly reduce production of EVs (Fig. 2A). In addition, we assessed whether it would be possible to block host-pathogen interactions following treatment with the EV-inhibitors. Indeed, both compounds were capable of decreasing trophozoites adhesion to the caco-2 monolayer through inhibition of EV release. In comparison, groups that were also treated with purified EVs had a higher adherence estimation (Fig. 2B).

On this basis, and as Cl-amidine was found to be the strongest EV-inhibitor, we further assessed if Cl-amidine affected the release of SEVs and LEVs equally. Protein estimation (Fig.2C) showed that treatment with 100 µM Cl-amidine reduced the production of both EV types. However, concentration of LEVs by NTA estimated a significant difference between treated compared to non-treated groups (~100 fold higher), while there was no difference observed for SEVs between treated versus control non-treated parasites (Fig.2D). The mean diameter (nm) of vesicles released in the presence of Cl-amidine was as follows: LEV (245.5), + Cl-am LEV (157.3), SEV (77.2), +Cl-am SEV (99.8) (Fig. 2E). Toxicity of caco-2 cells upon treatment with the EV-inhibitors was

insignificant in 48 hours-interval compared to the positive control albendazole, which is one of the reference drugs for Giardiasis treatment (Fig.2F).

***Host-pathogen interactions: both EV types are internalized by mammalian cells***

SEVs and LEVs were analyzed for their ability to interact with host cells. Among the fluorochromes tested for EV labelling only PKH-26 showed a homogeneous staining. Both PKH26-labelled LEVs and SEVs were incubated with caco-2 monolayers for 1 hour at two concentrations (7 or 14  $\mu$ g). Confocal microscopy revealed punctuated patterns of fluorescence distributed intracellularly (Fig.3A). Both populations appeared to be taken up by the host cells in a dose-dependent manner. LEV intensity internalization was overall observed to be higher, which may relate to larger vesicle size probably due to the bigger size of the particle (Fig. 3B)

***LEVs derived from protozoa, but not host EVs restore the lack of adhesion to host cell of *G. intestinalis* trophozoites treated with EV-inhibitors.***

Due to the identification of two EV populations, LEVs and SEVs, in *G. intestinalis*, we sought to verify if each EV population have the same phenotype effect on host cell adhesion. For this assay, two concentrations (7 or 14  $\mu$ g) from both EV subpopulations were used. Interestingly, LEVs derived from the protozoa were capable of restoring the adherence phenotype following treatment with Cl-amidine, in a dose-dependent manner (Fig.4A). In contrast, no effect was observed in the SEVs treated groups. These results suggest that physical properties related to adherence can be found in the larger *Giardia* EVs , and therefore EVs produced by the protozoa can selectively influence its phenotype.

Since a protozoa interaction with its host is complex and mediated through an active process, where it has been demonstrated that *Giardia* EVs participate in the adherence process, we also investigated if the host's EVs could contribute to this phenomenon. Caco-2 monolayers were washed and treated with Cl-amidine, and trophozoites were added to the wells, followed by treatment with caco-2 EVs (Figure 4B). Opposed to what observed for the trophozoite EVs, mammalian LEVs or SEVs had no phenotypical effect on trophozoite adhesion.

## Discussion

In this study, we describe two distinct EV populations from *Giardia intestinalis* where large EVs (LEVs), but not small EVs (SEVs), are associated with effective parasite cell adhesion to the host (Fig.5). Differing roles for these two EV populations, including in host-pathogen interactions, were demonstrated as treatment of *G. intestinalis* trophozoites with EV-inhibitors selectively decreased biogenesis of LEVs.

EVs from *Giardia* have previously been studied in host-pathogen interactions through proteomic analysis of excretory-secretory products (ESP), including EVs of axenic cultures and cultures of trophozoite interacting with mammalian cells, where proteins related to metabolism were found, without signal peptides on EVs (Ma'ayeh et al 2017). In addition, ESP containing cleavage activity through cysteine proteases have been identified (de la Mora-de la Mora et al., 2019). The secretome of extracellular protozoa are important for host manipulation and reports indicate a participation of EVs also in other models including *Acanthamoeba castellanii* (Gonçalves et al., 2018), *Trypanosoma brucei rhodeniense* (Geiger et al., 2010) and *Trichomonas vaginalis* (Twu et al., 2013).

While the majority of *Giardia* infected individuals are asymptomatic, giardiasis is a major contributor to malnutrition and growth impairment in children from developing countries (Fink & Singer, 2017). Additionally, the disease may also last for a long term as a chronic infection. For still unknown reasons, chronic development is associated with sequelae such as malnutrition, inflammatory manifestations, irritable bowel syndrome and extra-intestinal outcomes, including arthritis and food allergy (Hanevik et al, 2014; Bartelt & Sartor, 2015). Adaptive immunity is fundamental to parasite clearance, but leukocytes related with memory such as CD8<sup>+</sup> T also contribute to chronic inflammation (Scott et al, 2004). Since trophozoites secrete many virulence factors, which contribute to recurrent cycles of reinfection, their resistance to the most used drugs

(metronidazole, albendazole) has already been described (Upcroft, 1998; Arguelo-Garcia et al., 2015, Ansell et al., 2015) and the only licensed vaccine is solely used for veterinary practice. Therefore, it is important to identify and study novel clinical strategies that can lead to host recovery. Since PAD-inhibitor Cl-amidine and CBD can effectively decrease parasitic EV release, which contributes to parasite persistence into the small intestine, they may pose as novel therapeutic candidate agents for cases of chronic giardiasis. While important roles for arginine deiminase have previously been established in *Giardia* (Stadelmann et al., 2013; Trejo-Soto et al, 2016; Munoz-Cruz, 2018), a link to EV release has not been made before in *Giardia*. Cannabinoids have previously been linked to inhibition of parasite invasion and immunosuppression of trypanosomiasis (Nok et al., 1994; Croxford et al., 2005) as well as acting as anti-helmitics (Roulette et al., 2016), but their effects on *Giardia* have hitherto not been investigated. However, GiADI has PAD activity (Touz et al., 2008; Vranych et al., 2014). For example citrullination of the antigenic Variable Surface Proteins (VSPs) through arginine residues of its cytoplasmic tail results in lower antigenic switch, interfering in trophozoite fitness due to cytotoxic antibody activity (Touz et al., 2008). Furthermore, the incomplete conception of *G. intestinalis* pathophysiology and co-pathogen interactions needs to be improved to clarify when the protozoa begins the chronic outcome.

The field of EV research is still rapidly growing, with characterization of functions of subpopulations gaining increased attention. The complex function of LEVs revealed here in *Giardia*, suggests that their influence on phenotype could be even more diverse than those of SEVs (Tckach et al, 2018). No biomarkers were considered in the present study, since both EV populations are enriched mixtures of vesicles that fail to contain any unique marker (Kalra et al., 2013; Vader et al., 2016) and protozoa cells may have different sets of markers in their genome (Gonçalves et al., 2018; Ramirez et al., 2018).

Properties related to different functions of LEV have been studied in non-infectious models. For example, LEVs derived from cancer prostate cells contain substantially more large size ds DNA than SEVs (Vagner et al., 2018). LEVs (microvesicles) derived from platelets were also associated with polymorphonuclear leucocytes increase in adhesion (Fujimi et al., 2002). On the other hand, properties related to cellular adhesion for SEVs isolated from two

cancer cell lines have also been identified while the same was not detected for LEVs (Jimenez et al., 2019).

Two subsets of EVs have previously been identified in a parasite model (Cwiklinski et al., 2015), where LEVs contained cargo related to digestion (cathepsin L1 zymogen), while proteomic and functional analyses identified membrane structure components and immunomodulation factors in SEVs.

The pan-PAD-inhibitor Cl-amidine has previously been described as a potent EV- inhibitor, compared to a range of other compounds, in various cancer cells (Kosgodage et al., 2017, Kosgodage et al., 2018a), as well as to affect EV-mediated microRNA export (Kosgodage et al., 2019). Previous work has also suggested that PAD-inhibitors can be strategically used to sensitize cancer cells to chemotherapy (Kholia et al., 2015; Kosgodage et al., 2017). The EV-modulatory functions of CBD were recently revealed, and it has been found to be a more potent EV inhibitor than Cl-amidine in some cancers, also to have chemosensitizing effects and shows selective inhibition on smaller or larger EVs according to cancer type (Kosgodage et al., 2018b).

In the current study, both PAD-inhibitor and CBD were able to decrease adhesion of *Giardia* to mammalian cells, similar to as our group previously observed with the cholesterol-chelating agent methyl- $\beta$ -cyclodextrin treatment (Evans-Osses et al., 2017). For our protozoa model in the current study, Cl-amidine regulated LEVs specifically.

The mechanisms of EV biogenesis are still unclear and under ongoing investigation. Inhibition of specific proteins (TSG 101, STAM1 and HRS) has been shown to induce a decrease in exosome secretion, as well as protein content (Colombo et al., 2013). Silencing of specific effectors of the Rab family GTPases on HeLa B6H4 also inhibits exosome secretion, but without modifying cargo or morphology (Ostrowski et al., 2010). Roles for scramblase have been investigated in EV production in *Cryptococcus gattii* including effects on EV size and RNA cargo changes (Reis et al., 2019).

Biomolecular sorting in *G. intestinalis* EVs still needs to be fully understood, including that of acid nucleic populations. As the protozoa lacks a typical endosomal pathway, it is not known if cargo is targeted by post-translational modifications for vesicular secretion. Following the same perspective, not much

is understood about RNAi pathways for *Giardia*, although it is assumed that a post-translational machinery is necessary to synchronize both transcriptionally active nuclei of the parasite (Adam, 2001; Puccia et al., 2008). A post-transcriptional system related to antigenic switching has been described (Puccia et al., 2016). Serradell et al (2016), produced trophozoite clones expressing a collection of variable-specific surface proteins in plasma membrane through the knockdown of Dicer. Known miRNAs in *Giardia* are derived from hairpins codified in snoRNA (Saraiya et al., 2008; Saraiya et al., 2014). EV could be taken up and influence the host cell. Studies involving uptake from EV serum-derived were already reported for bacterial models (van Bergenhenegouwen et al., 2014; Hiemstra et al., 2014; Yu et al., 2019). However, to add a layer of complexity to the issue, uptake involving eukaryotic cells does not seem unspecific. For example, exosomes derived from oligodendrocytes were internalized (micropinocytosis) by microglia cells, but not by astrocytes (Fitzner et al., 2011). Ofir-Birin et al (2018) reported that *Plasmodium falciparum* derived EVs were processed in host monocytes, as well as their DNA cargo. Szempruch et al (2016) demonstrated that *Trypanosoma brucei* EVs are taken up by mammalian erythrocytes, resulting in anemia. This indicates that EVs accumulate on specific tissues, and that EV uptake can manipulate the host response.

It is possible that small RNAs involved in regulatory functions contained on *G. intestinalis* EVs could silence genes of intestinal immune response, permitting trophozoite adhesion and the low-course inflammation, characteristic of giardiasis. Lambertz et al (2015) observed delivery of small RNAs derived from *Leishmania* exosomes into macrophages, possibly regulating host-pathogen interactions.

## **Conclusion**

Our results suggest that the two EV populations identified in *G. intestinalis* so far, LEVs and SEVs, have distinct functions in the phenotype of this pathogen and can be selectively modulated using PAD-inhibitor and CBD. Luminal ecology needs to be investigated to completely understand the dual role of *Giardia* as a pathogen/commensal. Since adhesion in the epithelial intestine is fundamental to protozoa fitness, and LEVs clearly aid this process, the use of

selective EV-inhibitors, such as Cl-amidine, can be used to interfere with EV secretion, allowing novel strategies to enhance the control of giardiasis.

## Acknowledgements

We would like to thank Dr. Wanderson Da Rocha for sharing his laboratory at the Universidade Federal do Parana. Finally, this study has received support from FIOCRUZ, CNPq, CAPES and Programa Basico de Parasitologia AUXPE 2041/2011 (CAPES), Brazil. M.R is currently fellow from CNPq-Brazil.

## Competing interests

The authors declare no competing financial interests.

**Figure 1. Isolation and characterization of two distinct EV populations produced from *Giardia intestinalis*.** **A.** Protocol for the isolation of LEVs and SEVs based on differential centrifugation. **B.** Micro BCA protein estimation for the distinct EVs. **C.** Quantification of vesicle numbers from nanoparticle tracking analysis. **D.** Time-course for culture confluence of trophozoite induced to produce EVs for 1, 3 and 6 hours respectively. **E-F.** Particle size estimated by nanoparticle tracking analysis for LEVs (**E**) and SEVs (**F**).

**Figure 2. EV-inhibitors Cl-amidine and CBD decrease the production of LEVs secreted from *G. intestinalis*.** **A.** EV protein quantification post-treatment with Cl-amidine (Cl-am; 100 and 50  $\mu$ M) or CBD (10 and 5  $\mu$ M). **B.** Adhesion assay post-treatment with PAD-inhibitor (100  $\mu$ M) or CBD (10  $\mu$ M). **C.** Protein estimation for the distinct EV populations following Cl-am treatment (100  $\mu$ M) **D.** EV concentration estimation by nanoparticle tracking analysis (NTA) post-treatment with 100  $\mu$ M Cl-am. **E.** EV size estimation of the distinct EV populations by NTA. **F.** Cytotoxic effects of the EV-inhibitors on caco-2 monolayers. Cells were incubated for 48 h with ABZ (albendazole), Cl-am and

CBD at 10, 100, and 10  $\mu$ M respectively, or with culture medium. Cell viability was determined by the crystal violet method.

**Figure 3. Both *G. intestinalis* EVs populations are efficiently taken up by caco-2.** **A.** Caco-2 incubated with PKH26-labelled LEVs or SEVs. **B.** Internalized EVs were quantified by means of fluorescence intensity. Background signal was subtracted for every single image before obtaining the fluorescence intensity (Arbitrary Units); scale bars are indicated at 16  $\mu$ m.

**Figure 4. Protozoa derived EVs are selectively involved with protozoa adhesion to host cells.** **A.** Adhesion assay following treatment with distinct protozoa EV populations and 100  $\mu$ M Cl-amidine. **B.** Host-pathogen assay after treatment of caco-2 monolayer with Cl-amidine and incubation with mammalian cell derived EVs.

**Figure 5. *G. intestinalis* EV populations differentially restore adhesion of trophozoite treated with EV-inhibitors.**

## References

- Adam RD. Biology of *Giardia lamblia*. **Clin Microbiol Rev.** 2001 Jul;14(3):447-75.
- Amorim MG, Valieris R, Drummond RD, Pizzi MP, Freitas VM, Sinigaglia-Coimbra R, Calin GA, Pasqualini R, Arap W, Silva IT, Dias-Neto E, Nunes DN. A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies. **Sci Rep.** 2017 Oct 31;7(1):14395.
- Ankarklev J, Jerlström-Hultqvist J, Ringqvist E, Troell K, Svärd SG. Behind the smile: cell biology and disease mechanisms of *Giardia* species. **Nat Rev Microbiol.** 2010 Jun;8(6):413-22.
- Ansell BR, McConville MJ, Baker L, Korhonen PK, Young ND, Hall RS, Rojas CA, Svärd SG, Gasser RB, Jex AR. Time-Dependent Transcriptional Changes in Axenic *Giardia duodenalis* Trophozoites. **PLoS Negl Trop Dis.** 2015 Dec 4;9(12):e0004261.
- Argüello-García R, Cruz-Soto M, González-Trejo R, Luz María T., Maldonado P, M. Bazán-Tejeda L, Mendoza-Hernández G, Ortega-Pierres G. An antioxidant response is involved in resistance of *Giardia duodenalis* to albendazole. **Front Microbiol.** 2015; 6: 286.



Barash NR, Maloney JG, Singer SM, Dawson SC. *Giardia* Alters Commensal Microbial Diversity throughout the Murine Gut. **Infect Immun**. 2017 May 23;85(6). pii: e00948-16.

Bartelt LA, Bolick DT, Mayneris-Perxachs J, Kolling GL, Medlock GL, Zaenker EI, Donowitz J, Thomas-Beckett RV, Rogala A, Carroll IM, Singer SM, Papin J, Swann JR, Guerrant RL. Cross-modulation of pathogen-specific pathways enhances malnutrition during enteric co-infection with *Giardia lamblia* and enteroaggregative *Escherichia coli*. **PLoS Pathog**. 2017 Jul 27;13(7):e1006471.

Bartelt LA, Sartor RB. Advances in understanding *Giardia*: determinants and mechanisms of chronic sequelae. **F1000Prime Rep**. 2015; 7: 62.

Bayer-Santos E, Lima FM, Ruiz JC, Almeida IC, da Silveira JF. Characterization of the small RNA content of *Trypanosoma cruzi* extracellular vesicles. **Mol Biochem Parasitol**. 2014 193(2):71-4.

Blenkiron C, Simonov D, Muthukaruppan A, Tsai P, Dauros P, Green S, Hong J, Print CG, Swift S, Phillips AR. Uropathogenic *Escherichia coli* Releases Extracellular Vesicles That Are Associated with RNA. **PLoS One**. 2016; 11(8): e0160440.

Cernikova L, Faso C, Adrian BH. Five facts about *Giardia lamblia*. **PLoS Pathog**. 2018; 14(9).

Coakley G, Maizels RM, Buck AH. Exosomes and Other Extracellular Vesicles: The New Communicators in Parasite Infections. **Trends Parasitol**. 2015;31(10):477-489.

Coakley G, McCaskill JL, Borger JG, Simbari F, Robertson E, Millar M, Marcus Y, McSorley HJ, Maizels RM, Buck AH. Extracellular Vesicles from a Helminth Parasite Suppress Macrophage Activation and Constitute an Effective Vaccine for Protective Immunity. **Cell Rep**. 2017; 19(8): 1545–1557.

Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Théry C, Raposo G. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. **J Cell Sci**; 2013 Dec 15;126(Pt 24):5553-65.

Cotton JA, Amat CB, Buret AG. Disruptions of Host Immunity and Inflammation by *Giardia Duodenalis*: Potential Consequences for Co-Infections in the Gastro-Intestinal Tract. **Pathogens**. 2015 Dec; 4(4): 764–792.

Cwiklinski K, de la Torre-Escudero E, Trelis M, Bernal D, Dufresne PJ, Brennan GP, O'Neill S, Tort J, Paterson S, Marcilla A, Dalton JP, Robinson MW. The Extracellular Vesicles of the Helminth Pathogen, *Fasciola hepatica*: Biogenesis Pathways and Cargo Molecules Involved in Parasite Pathogenesis. **Mol Cell Proteomics**. 2015;14(12):3258-73.

Croxford JL, Wang K, Miller SD, Engman DM, Tyler KM. Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression. **Cell Microbiol**. 2005 7(11):1592-602.

de la Mora-de la Mora JI, Enríquez-Flores S, Fernández-Lainez C, Gutiérrez-Castrellón P, Olivos-García A, González-Canto A, Hernández R, Luján HD, García-Torres I, López-Velásquez. Characterization of proteolytic activities of *Giardia lamblia* with the ability to cleave His-tagged N-terminal sequences. **Mol & Biochem Parasitol.** 2019 (228): 16-23.

Evans-Osses I, Mojoli A, Monguió-Tortajada M, Marcilla A, Aran V, Amorim M, Inal J, Borràs FE, Ramirez MI. Microvesicles released from *Giardia intestinalis* disturb host-pathogen response in vitro. **Eur J Cell Biol.** 2017;96(2):131-142.

Fink MY, Singer SM. The Intersection of Immune Responses, Microbiota, and Pathogenesis in Giardiasis. **Trends Parasitol.** 2017;33(11):901-913.

Fitzner D, Schnaars M, van Rossum D, Krishnamoorthy G, Dibaj P, Bakhti M, Regen T, Hanisch UK, Simons M. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. **J Cell Sci.** 2011 Feb 1;124(Pt 3):447-58

Fujimi S, Ogura H, Tanaka H, Koh T, Hosotsubo H, Nakamori Y, Kuwagata Y, Shimazu T, Sugimoto H. Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. **J Trauma.** 2002;52(3):443-8.

Gonçalves DS, Ferreira MS, Liedke SC, Gomes KX, Oliveira GA, Leão PEL, Cesar GV, Seabra SH, Cortines JR, Casadevall A, Nimrichter L, Domont GB, Junqueira MR, Peralta JM, Guimaraes AJ. Extracellular vesicles and vesicle-free secretome of the protozoa *Acanthamoeba castellanii* under homeostasis and nutritional stress and their damaging potential to host cells. **Virulence.** 2018; 9(1): 818–836.

György B, Toth E, Tarcsa E, Falus A, Buzas EI. Citrullination: a posttranslational modification in health and disease. **Int. J. Biochem. Cell Biol.** 2006, V.38, pp. 1662-1677.

Halliez MCM, Buret AG. Extra-intestinal and long term consequences of *Giardia duodenalis* infections. **World J Gastroenterol.** 2013; 19(47): 8974–8985.

Hanevik K, Wensaas KA, Rortveit G, Eide GE, Mørch K, Langeland N. Irritable bowel syndrome and chronic fatigue 6 years after *Giardia* infection: a controlled prospective cohort study. **Clin Infect Dis.** 2014;59(10):1394-400.

Hernández-Cervantes R, Méndez-Díaz M, Prospéro-García Ó, Morales-Montor J. (2017). Immunoregulatory Role of Cannabinoids during Infectious Disease. **Neuroimmunomodulation.** 2017;24(4-5):183-199.

Hiemstra TF, Charles PD, Gracia T, Hester SS, Gatto L, Al-Lamki R, Floto RA, Su Y, Skepper JN, Lilley KS, Karet Frankl FE. Human urinary exosomes as innate immune effectors. **J Am Soc Nephrol.** 2014 Sep;25(9):2017-27.

Jeffrey CJ. Protein moonlighting: what is it, and why is it important? **Philos. Trans. R. Soc. Lond. B Biol. Sci.** 2018, 373 (1738)

Jimenez L, Yu H, McKenzie AJ, Franklin JL, Patton JG, Liu Q, Weaver AM. Quantitative Proteomic Analysis of Small and Large Extracellular Vesicles (EVs) Reveals Enrichment of Adhesion Proteins in Small EVs. **J. Proteome Res** E-pub ahead of print. DOI: 10.1021/acs.jproteome.8b00647.

Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, Hulett MD, Mathivanan S. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. **Proteomics**. 2013 13(22):3354-64.

Keister DB. Axenic culture of *Giardia lamblia* in TYI-S-33 medium supplemented with bile. **Trans R Soc Trop Med Hyg** 1983, 77: 487–488

Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D, Gorospe M. RNA in extracellular vesicles. **Wiley Interdiscip Rev RNA**. 2017 ;8(4).

Kosgodage US, Trindade RP, Thompson PR, Inal JM, Lange S. Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy. **Int J Mol Sci**. 2017; 18(5): 1007.

Kosgodage US, Uysal-Onganer P, MacLatchy A, Nicholas AP, Inal JM, Lange S. Peptidylarginine Deiminases Post-translationally deiminate Prohibitin and modulate Extracellular Vesicle Release and microRNAs in Glioblastoma Multiforme. **Int J Mol Sci** 2018a; 20(1):103.

Kosgodage US, Mould R, Henley AB, Nunn AV, Guy GW, Thomas EL, Inal JM, Bell JD, Lange S. Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer. **Front Pharmacol**. 2018b; 9:889.

Kosgodage US, Uysal-Onganer P, MacLatchy A, Mould R, Nunn AV, Guy GW, Kraev I, Chatterton NP, Thomas EL, Inal JM, Bell JD, Lange S. Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells. **Transl Oncol**. 2019; 12(3):513-522.

Lambertz U, Oviedo Ovando ME, Vasconcelos EJ, Unrau PJ, Myler PJ, Reiner NE. Small RNAs derived from tRNAs and rRNAs are highly enriched in exosomes from both old and new world *Leishmania* providing evidence for conserved exosomal RNA Packaging. **BMC Genomics**. 2015;16:151.

Lange S, Gallagher M, Kholia S, Kosgodage US, Hristova M, Hardy J, Inal JM. Peptidylarginine Deiminases-Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release? **Int J Mol Sci**. 2017;18(6). pii: E1196.

Liu J, Ma'ayeh S, Peirasmaki D, Lundström-Stadelmann B, Hellman L, Svärd SG. Secreted *Giardia intestinalis* cysteine proteases disrupt intestinal epithelial cell junctional complexes and degrade chemokines. **Virulence**. 2018; 9(1): 879–894.

Maas SLN, Breakefield XO, Weaver AM. Extracellular Vesicles: Unique Intercellular Delivery Vehicles. **Trends Cell Biol.** 2017 Mar;27(3):172-188.

Ma'ayeh SY, Liu J, Peirasmaki D, Hörnaeus K, Bergström Lind S, Grabherr M, Bergquist J, Svärd SG. Characterization of the *Giardia intestinalis* secretome during interaction with human intestinal epithelial cells: The impact on host cells. **PLoS Negl Trop Dis.** 2017;11(12):e0006120.

Magnadottir B, Hayes P, Hristova M, Bragason B Th, Nicholas AP, Dodds AW, Gudmundsdottir S, Lange S. Post-translational protein deimination in cod (Gadus morhua L.) ontogeny – novel roles in tissue remodelling and mucosal immune defences? **Dev. Comp. Immunol.** 2018; 87:157-170

McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. **Cell Cycle.** 2014;13(9):1400-12.

Mechoulam, R., Parker, L. A., and Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. **J. Clin. Pharmacol.** 42: 11S–19S.

Morrison EE, Bailey MA, Dear JW. Renal extracellular vesicles: from physiology to clinical application. **J Physiol.** 2016 594(20):5735-5748.

Muñoz-Cruz S, Gomez-García A, Matadamas-Martínez F, Alvarado-Torres JA, Meza-Cervantez P, Arriaga-Pizano L, Yépez-Mulia L. Giardia lamblia: identification of molecules that contribute to direct mast cell activation. **Parasitol Res.** 2018; 117(8):2555-2567.

Nok AJ, Ibrahim S, Arowosafe S, Longdet I, Ambrose A, Onyenekwe PC, Whong CZ. The trypanocidal effect of Cannabis sativa constituents in experimental animal trypanosomiasis. **Vet Hum Toxicol.** 1994; 36(6):522-4.

Ofir-Birin Y, Abou Karam P, Rudik A, Giladi T, Porat Z, Regev-Rudzki N. Monitoring Extracellular Vesicle Cargo Active Uptake by Imaging Flow Cytometry. **Front Immunol.** 2018 May 24;9:1011.

Ostrowski M, Carmo NB, Krumeich S, Fagnet I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, Goud B, Benaroch P, Hacoheh N, Fukuda M, Desnos C, Seabra MC, Darchen F, Amigorena S, Moita LF, Thery C. Rab27a and Rab27b control different steps of the exosome secretion pathway. **Nat Cell Biol.** 2010 Jan;12(1):19-30; sup pp 1-13.

Prucca CG, Slavin I, Quiroga R, Elías EV, Rivero FD, Saura A, Carranza PG, Luján HD. Antigenic variation in *Giardia lamblia* is regulated by RNA interference. **Nature.** 2008;456(7223):750-4.

Ramirez MI, Amorim MG, Gadelha C, Milic I, Welsh JA, Freitas VM, Nawaz M, Akbar N, Couch Y, Makin L, Cooke F, Vettore AL, Batista PX, Freezor R, Pezuk JA, Rosa-Fernandes L, Carreira ACO, Devitt A, Jacobs L, Silva IT, Coakley G, Nunes DN, Carter D, Palmisano G, Dias-Neto E. Technical challenges of working with extracellular vesicles. **Nanoscale.** 2018;10(3):881-906.

Reis FCG, Borges BS, Jozefowicz LJ, Sena BAG, Garcia AWA, Medeiros LC, Martins ST, Honorato L, Schrank A, Vainstein MH, Kmetzsch L, Nimrichter L, Alves LR, Staats CC, Rodrigues ML. A Novel Protocol for the Isolation of Fungal Extracellular Vesicles Reveals the Participation of a Putative Scramblase in Polysaccharide Export and Capsule Construction in *Cryptococcus gattii*. **mSphere**. 2019 Mar 20;4(2).

Resch U, Tsatsaronis JA, Le Rhun A, Stübiger G, Rohde M, Kasvandik S, Holzmeister S, Tinnefeld P, Wai SN, Charpentier E. A Two-Component Regulatory System Impacts Extracellular Membrane-Derived Vesicle Production in Group A *Streptococcus*. **MBio**. 2016;7(6). pii: e00207-16.

Roulette CJ, Kazanji M, Breurec S, Hagen EH. (2016). High prevalence of cannabis use among Aka foragers of the Congo Basin and its possible relationship to helminthiasis. **Am J Hum Biol**. 2016;28(1):5-15.

Ryu A, Kim DH, Kim E, Lee MY. The Potential Roles of Extracellular Vesicles in Cigarette Smoke-Associated Diseases. **Oxid Med Cell Longev**. 2018; 2018: 4692081.

Saraiya AA, Li W, Wang CC. A microRNA derived from an apparent canonical biogenesis pathway regulates variant surface protein gene expression in *Giardia lamblia*. **RNA**. 2011 17(12): 2152–2164.

Saraiya AA, Li W, Wu J, Chang CH, Wang CC. The microRNAs in an Ancient Protist Repress the Variant-Specific Surface Protein Expression by Targeting the Entire Coding Sequence. **PLoS Pathog**. 2014; 10(2): e1003791.

Savioli L, Smith H, Thompson A. *Giardia* and *Cryptosporidium* join the 'Neglected Diseases Initiative'. **Trends Parasitol**. 2006;22(5):203-8.

Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. **Nat Methods**. 2012;9(7):671-5.

Scott KG, Yu LC, Buret AG. Role of CD8+ and CD4+ T lymphocytes in jejunal mucosal injury during murine giardiasis. **Infect Immun**. 2004;72(6):3536-42.

Serradell MC, Saura A, Rupil LL, Gargantini PR, Faya MI, Furlan PJ, Hugo, Lujan HD. Vaccination of domestic animals with a novel oral vaccine prevents *Giardia* infections, alleviates signs of giardiasis and reduces transmission to humans. **NPJ Vaccines**. 2016; 1: 16018.

Ślōmka A, Urban SK, Lukacs-Kornek V, Żekanowska E, Kornek M. Large Extracellular Vesicles: Have We Found the Holy Grail of Inflammation? **Front Immunol**. 2018;9:2723.

Sork H, Corso G, Krjutskov K, Johansson HJ, Nordin JZ, Wiklander OPB, Lee YXF, Westholm JO, Lehtiö J, Wood MJA, Mäger I, El Andaloussi S. Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome. **Sci Rep**. 2018;8(1):10813.

Stadelmann B, Hanevik K, Andersson MK, Bruserud O, Svärd SG. The role of arginine and arginine-metabolizing enzymes during *Giardia* - host cell interactions in vitro. **BMC Microbiol.** 2013; 13:256.

Szempruch AJ, Sykes SE, Kieft R, Denison L, Becker AC, Gartrell A, Martin WJ, Nakayasu ES, Almeida IC, Hajduk SL, Harrington JM. Extracellular vesicles from *Trypanosoma brucei* mediate virulence factor transfer and cause host anemia. **Cell.** 2016; Jan 14; 164(0): 246–257.

Tkach M, Kowal J, Théry C. Why the need and how to approach the functional diversity of extracellular vesicles. **Philos Trans R Soc Lond B Biol Sci.** 2018;373(1737). pii: 20160479.

Touz MC, Feliziani C, Rópolo AS. Membrane-Associated Proteins in *Giardia lamblia*. **Genes (Basel).** 2018; 9(8): 404.

Touz MC, Rópolo AS, Rivero MR, Vranych CV, Conrad JT, Svard SG, Nash TE. Arginine deiminase has multiple regulatory roles in the biology of *Giardia lamblia*. **J Cell Sci.** 2008 Sep 1;121(Pt 17):2930-8.

Tsatsaronis JA, Franch-Arroyo S, Resch U, Charpentier E. Extracellular Vesicle RNA: A Universal Mediator of Microbial Communication? **Trends Microbiol.** 2018;26(5):401-410.

Trejo-Soto PJ, Aguayo-Ortiz R, Yépez-Mulia L, Hernández-Campos A, Medina-Franco JL, Castillo R. Insights into the structure and inhibition of *Giardia intestinalis* arginine deiminase: homology modeling, docking, and molecular dynamics studies. **J Biomol Struct Dyn.** 2016;34(4):732-48.

Twu O, de Miguel N, Lustig G, Stevens GC, Vashisht AA, Wohlschlegel JÁ, Johnson PJ. *Trichomonas vaginalis* Exosomes Deliver Cargo to Host Cells and Mediate Host:Parasite Interactions. **PLoS Pathog.** 2013 Jul; 9(7): e1003482.

Upcroft P. Drug resistance in *Giardia*: clinical versus laboratory isolates. **Drug Resist Updat.** 1998;1(3):166-8.

Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. **Adv Drug Deliv Rev.** 2016 Nov 15;106(Pt A):148-156.

Vagner T, Spinelli C, Minciocchi VR, Balaj L, Zandian M, Conley A, Zijlstra A, Freeman MR, Demichelis F, De S, Posadas EM, Tanaka H, Vizio DD. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. **J Extracell Vesicles.** 2018; 7(1): 1505403.

van Bergenhenegouwen J, Kraneveld AD, Rutten L, Kettelarij N, Garssen J, Vos AP. Extracellular vesicles modulate host-microbe responses by altering TLR2 activity and phagocytosis. **PLoS One.** 2014 Feb 20;9(2):e89121.

van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. **Nat Rev Mol Cell Biol.** 2018;19(4):213-228.

Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. **Bioessays**. 2003; 25 (11) :1106-1118.

Vranych CV, Rivero MR, Merino MC, Mayol GF, Zamponi N, Maletto BA, Pistoiresi-Palencia MC, Touz MC, Rópolo AS. SUMOylation and deimination of proteins: two epigenetic modifications involved in *Giardia* encystation. **Biochim Biophys Acta**. 2014 Sep;1843(9):1805-17.

Wang S, Wang Y. Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. **Biochim. Biophys. Acta**, 2013; 1829 (10):1126-1135.

Witalison EE, Thompson PR, Hofseth LJ). Protein arginine deiminases and associated citrullination: physiological functions and diseases associated with dysregulation. **Curr. Drug Targets**, 2015; 16 (7):700-710. Yu S, Zhao Z, Xu X, Li M, Li P. Characterization of three different types of extracellular vesicles and their impact on bacterial growth. **Food Chem**, 2019; 272: 372-378.











